…the panel considers pembrolizumab immunotherapy to be useful in certain circumstances (ie, in patients with MSI-high/deficient MMR [MSI-H/dMMR] or tumor mutation burden-high [TMB-H] tumors).

KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated:...for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.